# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...
Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $...
Wedbush analyst Laura Chico maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target ...
Longboard Pharmaceuticals (NASDAQ:LBPH) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimat...
Baird analyst Joel Beatty initiates coverage on Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform rating and announc...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...
Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $...
PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annua...
HC Wainwright & Co. analyst Patrick Trucchio maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains ...